3 Sterile Injectables, Chronic Care Brands and Biologics Maker Stocks With a Strong Future Roadmap: Gland Pharma, Eris Lifesciences and Shilpa Medicare
- October 21, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Gland Pharma, Eris Lifesciences and Shilpa Medicare: ROE of 9.4% to 15.9% and FY22 to FY26 revenue CAGR of 7.5% to 22.9%. Prices as of 20 Oct 2026.
Quick Answer
The three injectable and specialty pharma stocks to watch are Gland Pharma, Eris Lifesciences and Shilpa Medicare. Their return on equity ranges from 9.4% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 22.9%. Eris Lifesciences leads on both return on equity at 15.9% and revenue growth at 22.9% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.
Injectable and specialty pharma stocks focus on products that need advanced skills and earn steady demand from hospitals and doctors. Gland Pharma, Eris Lifesciences and Shilpa Medicare cover a sterile injectables maker, a chronic care branded formulations company and a biologics and ingredient group.
This list covers three injectable and specialty pharma stocks with complete current figures: Gland Pharma, Eris Lifesciences and Shilpa Medicare. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Injectable and Specialty Pharma Stocks?
Injectable and specialty pharma stocks are listed companies that make sterile injections, biologics or branded chronic care medicines. Their earnings follow product approvals, hospital demand, prescription trends and plant utilisation.
Injectable and Specialty Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Gland Pharma | 3,019.8 | 49,953 | 44.2 | 36.0 | 9.9 | 0.03 |
| Eris Lifesciences | 1,120.4 | 15,618 | 23.5 | 36.0 | 15.9 | 0.60 |
| Shilpa Medicare | 876.2 | 17,132 | 57.6 | 36.0 | 9.4 | 0.25 |
On valuation, Eris Lifesciences trades at a P/E below the industry P/E, while Gland Pharma and Shilpa Medicare trade above it, which reflects the growth the market already expects. Readers comparing injectable and specialty pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Injectable and Specialty Pharma Stocks Have a Strong Roadmap in India?
Injectable and specialty pharma stocks have a strong roadmap in India because injectables, biologics and chronic therapies are growing categories where few suppliers can meet quality standards.
- Injectable demand. Hospitals use rising volumes of sterile medicines for surgery and cancer care.
- Chronic therapies. Diabetes, heart and gut conditions create repeat prescriptions.
- Biologics pipeline. Complex medicines made from living cells open higher-value markets.
Why Gland Pharma Features Among These Injectable and Specialty Pharma Stocks
Among the injectable and specialty pharma stocks on this list, Gland Pharma is a Hyderabad-based maker of sterile injectable medicines and a leading contract manufacturer for global drug companies, with plants in India and Europe.
Revenue rose from Rs 4,625 crore in FY22 to Rs 6,747 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 781 crore in FY23 to Rs 1,027 crore in FY26, which works out to a compound annual growth rate of 9.6%.
In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,862 crore, while net profit rose 47.1% to Rs 317 crore. The company has a return on equity of 9.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 49,953 crore. The stock trades at a P/E of 44.2, above the industry P/E of 36.0.
Roadmap: Injectables are a segment where few suppliers have the technical and regulatory capability, and the company serves customers across more than 60 countries. Its partnerships with large marketers and its expanded European base support growth.
What to watch: Check new product launches and utilisation of its manufacturing capacity.
Why Eris Lifesciences Features Among These Injectable and Specialty Pharma Stocks
Among the sterile injectable shares on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.
In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%.
Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.
Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.
What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.
Why Shilpa Medicare Features Among These Injectable and Specialty Pharma Stocks
Among the three companies on this list, Shilpa Medicare, headquartered in Raichur, Karnataka, is a pharmaceutical company with active ingredients, formulations, biologics and contract development and manufacturing under one roof, with a focus on oncology.
The company has a return on equity of 9.4%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 17,132 crore. The stock trades at a P/E of 57.6, above the industry P/E of 36.0.
Revenue rose from Rs 1,160 crore in FY22 to Rs 1,549 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 60.6 crore in FY22 to Rs 243 crore in FY26, which works out to a compound annual growth rate of 41.6%. In the June 2026 quarter, revenue grew 43.0% year on year to Rs 469 crore, while net profit rose 115.1% to Rs 101 crore.
Roadmap: Its path forward combines a growing biologics and specialty injectables pipeline with contract manufacturing for global partners. Multiple business lines give it more than one route to scale as regulatory approvals arrive.
What to watch: Follow regulatory approvals and commercial launches, since these drive the timing of earnings.
Gland Pharma vs Eris Lifesciences vs Shilpa Medicare on Key Financials
The table below sets the three injectable and specialty pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Gland Pharma | 4,625 | 6,747 | 9.9% | 1,027 | 15.2% |
| Eris Lifesciences | 1,373 | 3,137 | 22.9% | 648 | 20.6% |
| Shilpa Medicare | 1,160 | 1,549 | 7.5% | 243 | 15.7% |
Eris Lifesciences posts the highest return on equity in this group at 15.9%. Gland Pharma has the largest FY26 revenue at Rs 6,747 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with injectable and specialty pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Gland Pharma | 1,563 | 1,862 | 19.1% |
| Eris Lifesciences | 776 | 876 | 12.9% |
| Shilpa Medicare | 328 | 469 | 43.0% |
Key Risks to Check Before Investing in Injectable and Specialty Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these injectable and specialty pharma stocks, the main points are: Long-term sterile injectable shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Approval timelines. Product launches depend on regulatory clearances.
- Plant inspections. Quality audits can influence supply.
- Customer concentration. Contract manufacturing relies on a limited set of large customers.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter injectable and specialty pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Injectable and Specialty Pharma Stocks
Injectable and specialty pharma stocks suit investors who prefer technically demanding segments. Gland Pharma, Eris Lifesciences and Shilpa Medicare each have a distinct capability that is hard to copy. Based on the 20 October 2026 close, Gland Pharma trades at Rs 3,019.8, Eris Lifesciences at Rs 1,120.4 and Shilpa Medicare at Rs 876.2. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these injectable and specialty pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track injectable and specialty pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are injectable and specialty pharma stocks?
Ans. Injectable and specialty pharma stocks are listed companies that make sterile injections, biologics or branded chronic care medicines. Their earnings follow product approvals, hospital demand, prescription trends and plant utilisation. This list looks at three of them, Gland Pharma, Eris Lifesciences and Shilpa Medicare, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.
Which injectable and specialty pharma stocks are covered in this list?
Ans. This list covers Gland Pharma, Eris Lifesciences and Shilpa Medicare. Based on the 20 October 2026 close, Gland Pharma traded at Rs 3,019.8, Eris Lifesciences at Rs 1,120.4 and Shilpa Medicare at Rs 876.2. Their return on equity ranges from 9.4% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 22.9%.
Why do injectable and specialty pharma stocks have a strong future roadmap in India?
Ans. Injectable and specialty pharma stocks have a strong roadmap in India because injectables, biologics and chronic therapies are growing categories where few suppliers can meet quality standards. The main drivers are as follows. Injectable demand. Hospitals use rising volumes of sterile medicines for surgery and cancer care. Chronic therapies. Diabetes, heart and gut conditions create repeat prescriptions. Biologics pipeline. Complex medicines made from living cells open higher-value markets. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Gland Pharma performed financially?
Ans. Revenue rose from Rs 4,625 crore in FY22 to Rs 6,747 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 781 crore in FY23 to Rs 1,027 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 19.1% year on year to Rs 1,862 crore, while net profit rose 47.1% to Rs 317 crore. The company has a return on equity of 9.9%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 49,953 crore. The stock trades at a P/E of 44.2, above the industry P/E of 36.0. Looking ahead, injectables are a segment where few suppliers have the technical and regulatory capability, and the company serves customers across more than 60 countries. Its partnerships with large marketers and its expanded European base support growth.
How has Eris Lifesciences performed financially?
Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.
How has Shilpa Medicare performed financially?
Ans. Revenue rose from Rs 1,160 crore in FY22 to Rs 1,549 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 60.6 crore in FY22 to Rs 243 crore in FY26, which works out to a compound annual growth rate of 41.6%. In the June 2026 quarter, revenue grew 43.0% year on year to Rs 469 crore, while net profit rose 115.1% to Rs 101 crore. The company has a return on equity of 9.4%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 17,132 crore. The stock trades at a P/E of 57.6, above the industry P/E of 36.0. Looking ahead, its path forward combines a growing biologics and specialty injectables pipeline with contract manufacturing for global partners. Multiple business lines give it more than one route to scale as regulatory approvals arrive.
What risks should investors check before buying injectable and specialty pharma stocks?
Ans. Investors should check a few risks before buying injectable and specialty pharma stocks. Approval timelines. Product launches depend on regulatory clearances. Plant inspections. Quality audits can influence supply. Customer concentration. Contract manufacturing relies on a limited set of large customers. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of injectable and specialty pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.